Hims & Hers adds five compounded treatments to Peptides+

Hims & Hers Health is launching five U.S.-compounded peptide and longevity formulations through its Peptides+ platform, while acknowledging that more research is needed to understand how best to use them and how effective they are. None of the specific products is approved by the Food and Drug Administration.

Today, 17:06
155 0
Hims & Hers adds five compounded treatments to Peptides+

The offerings follow a federal easing of restrictions on compounding certain unapproved peptides, short chains of amino acids that have gained popularity among fitness and longevity enthusiasts. Users credit them with muscle growth, faster injury recovery and anti-aging effects, but most lack evidence from robust human trials.

The initial products are sermorelin, glutathione, nicotinamide adenine dinucleotide (NAD+), vitamin B-12 and L-carnitine. Sermorelin stimulates growth-hormone release and is marketed for recovery, body composition and anti-aging. Glutathione is promoted for anti-aging and athletic recovery, while NAD+ plays a role in cellular metabolism. Vitamin B-12 supports red blood cell production, DNA formation and nerve function; L-carnitine helps the body convert fat into energy.

The FDA has approved certain prescription forms of B-12 and L-carnitine for established medical uses, primarily diagnosed deficiencies. Hims said its compounded products are authorized by law and made by pharmacies that meet quality standards and are licensed and inspected by state boards of pharmacy.

More than 10,000 people signed up for the company’s early-access list within 15 days of its launch in late October, a spokesperson said. Hims plans to add more U.S.-made peptides and therapies, including BPC-157 and TB-500. Both are unapproved and marketed for healing or soft-tissue recovery; most research on them has been conducted in animals rather than humans.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!